📊 KBLB Key Takeaways
Is Kraig Biocraft Laboratories, Inc. (KBLB) a Good Investment?
Kraig Biocraft Laboratories faces critical financial distress with zero revenue generation, negative $8.0M stockholders' equity, and only approximately 12 months of cash runway at current burn rates. The combination of persistent operating losses of $3.6M annually, negative operating cash flow, and technical insolvency indicates high probability of restructuring or liquidation without immediate operational turnaround.
Kraig Biocraft Laboratories remains pre-revenue with persistent operating losses and extremely weak liquidity (current ratio 0.18x), resulting in negative equity and deeply negative ROA. With limited cash relative to sizable current liabilities, going-concern and financing risks are high absent near-term commercialization and balance sheet repair.
Why Buy Kraig Biocraft Laboratories, Inc. Stock? KBLB Key Strengths
- Modest long-term debt of $8.8K limits leverage burden and provides restructuring flexibility
- Maintains $1.8M in cash reserves providing near-term operational window for strategic alternatives
- Non-zero asset base of $2.6M offers some liquidation value floor
- Minimal long-term debt and interest burden
- Capex-light model, keeping fixed investment needs low
- Some cash on hand to pursue near-term milestones
KBLB Stock Risks: Kraig Biocraft Laboratories, Inc. Investment Risks
- Zero revenue generation indicates non-operational status with no documented path to market validation or profitability
- Negative stockholders' equity of -$8.0M combined with 0.18x current ratio signals imminent insolvency and bankruptcy risk
- Negative operating cash flow of -$1.8M annually with depleting reserves creates approximately 12-month operational runway before capital depletion
- Severe liquidity shortfall and negative equity imply insolvency/dilution risk
- Continued cash burn with no revenue; dependence on external financing
- Execution risk: delays in commercialization could exhaust runway
Key Metrics to Watch
- Quarterly revenue generation - any revenue would indicate operational progress and market validation
- Monthly operating cash burn rate - critical for determining remaining cash runway and restructuring timeline
- Stockholders' equity trend - movement toward positive territory would signal stabilization or successful capital injection
- Revenue growth (from zero)
- Operating cash flow (burn/runway)
Kraig Biocraft Laboratories, Inc. (KBLB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
KBLB Profit Margin, ROE & Profitability Analysis
KBLB vs Materials Sector: How Kraig Biocraft Laboratories, Inc. Compares
How Kraig Biocraft Laboratories, Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kraig Biocraft Laboratories, Inc. Stock Overvalued? KBLB Valuation Analysis 2026
Based on fundamental analysis, Kraig Biocraft Laboratories, Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kraig Biocraft Laboratories, Inc. Balance Sheet: KBLB Debt, Cash & Liquidity
KBLB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kraig Biocraft Laboratories, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
KBLB Revenue Growth, EPS Growth & YoY Performance
KBLB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2021 | N/A | -$568.8K | N/A |
| Q3 2019 | N/A | -$207.0K | N/A |
| Q2 2019 | N/A | -$188.6K | N/A |
| Q1 2019 | N/A | -$278.9K | N/A |
| Q3 2018 | $27.2K | -$207.0K | N/A |
| Q2 2018 | N/A | -$188.6K | N/A |
| Q1 2018 | N/A | -$278.9K | N/A |
| Q3 2017 | $18.7K | -$279.8K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kraig Biocraft Laboratories, Inc. Dividends, Buybacks & Capital Allocation
KBLB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kraig Biocraft Laboratories, Inc. (CIK: 0001413119)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KBLB
What is the AI rating for KBLB?
Kraig Biocraft Laboratories, Inc. (KBLB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KBLB's key strengths?
Claude: Modest long-term debt of $8.8K limits leverage burden and provides restructuring flexibility. Maintains $1.8M in cash reserves providing near-term operational window for strategic alternatives. ChatGPT: Minimal long-term debt and interest burden. Capex-light model, keeping fixed investment needs low.
What are the risks of investing in KBLB?
Claude: Zero revenue generation indicates non-operational status with no documented path to market validation or profitability. Negative stockholders' equity of -$8.0M combined with 0.18x current ratio signals imminent insolvency and bankruptcy risk. ChatGPT: Severe liquidity shortfall and negative equity imply insolvency/dilution risk. Continued cash burn with no revenue; dependence on external financing.
What is KBLB's revenue and growth?
Kraig Biocraft Laboratories, Inc. reported revenue of $0.0.
Does KBLB pay dividends?
Kraig Biocraft Laboratories, Inc. does not currently pay dividends.
Where can I find KBLB SEC filings?
Official SEC filings for Kraig Biocraft Laboratories, Inc. (CIK: 0001413119) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KBLB's EPS?
Kraig Biocraft Laboratories, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KBLB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kraig Biocraft Laboratories, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KBLB stock overvalued or undervalued?
Valuation metrics for KBLB: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy KBLB stock in 2026?
Our dual AI analysis gives Kraig Biocraft Laboratories, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KBLB's free cash flow?
Kraig Biocraft Laboratories, Inc.'s operating cash flow is $-1.8M, with capital expenditures of $5.4K.
How does KBLB compare to other Materials stocks?
Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio 0.18 (avg: 1.6).